Thymalin vs Cagrilintide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Thymalin
Thymalin is a polypeptide preparation derived from calf thymus. Developed in Russia, it has been used for decades to support immune function and has shown potential anti-aging effects in long-term studies.
Full details →Cagrilintide
Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.
Full details →Side-by-Side Comparison
| Aspect | Thymalin | Cagrilintide |
|---|---|---|
| Mechanism | Regulates the ratio of T-cell subpopulations, stimulates cellular immunity, and enhances phagocytosis. Also affects neuroendocrine regulation and may influence melatonin production. | Activates amylin receptors (calcitonin receptor with RAMP proteins) to slow gastric emptying, suppress glucagon secretion, and reduce food intake through central satiety mechanisms distinct from GLP-1. |
| Typical Dosage | Clinical protocols: 5-20mg daily intramuscularly for 3-10 days. Often cycled 1-2 times per year for maintenance. | Clinical trials: 2.4mg weekly as monotherapy or in combination with semaglutide 2.4mg (CagriSema). Optimal dosing still being determined. |
| Administration | Intramuscular injection. Usually administered in short courses rather than continuously. Often combined with Epithalamin for anti-aging protocols. | Subcutaneous injection once weekly. Currently only available in clinical trials - not yet FDA approved. |
| Side Effects | Generally well-tolerated. May cause injection site reactions or temporary flu-like symptoms as immune function is modulated. | Nausea, vomiting, diarrhea, constipation similar to other incretin-based therapies. Combination with semaglutide may increase GI effects initially. |
| Best For |